Year |
Citation |
Score |
2023 |
McElvaney OJ, Heltshe SL, Odem-Davis K, West NE, Sanders DB, Fogarty B, VanDevanter DR, Flume PA, Goss CH. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. Annals of the American Thoracic Society. PMID 38096105 DOI: 10.1513/AnnalsATS.202308-673OC |
0.312 |
|
2023 |
Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, Sanders DB, West NE, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, LiPuma JJ. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society. PMID 37963297 DOI: 10.1513/AnnalsATS.202306-576OC |
0.357 |
|
2023 |
Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Annals of the American Thoracic Society. PMID 37683122 DOI: 10.1513/AnnalsATS.202303-245OC |
0.379 |
|
2023 |
McElvaney OJ, Heltshe SL, Odem-Davis K, West NE, Sanders DB, Fogarty B, VanDevanter DR, Flume PA, Goss CH. Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 37407341 DOI: 10.1016/j.jcf.2023.06.012 |
0.36 |
|
2023 |
Cogen JD, Sanders DB, Slaven JE, Faino AV, Somayaji R, Gibson RL, Hoffman LR, Ren CL. Antibiotic Regimen Changes During Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment. Annals of the American Thoracic Society. PMID 37327485 DOI: 10.1513/AnnalsATS.202301-078OC |
0.355 |
|
2023 |
Heltshe SL, Russell R, VanDevanter DR, Sanders DB. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 36803635 DOI: 10.1016/j.jcf.2023.02.006 |
0.329 |
|
2022 |
Rosenfeld M, Ostrenga J, Cromwell EA, Magaret A, Szczesniak R, Fink A, Schechter MS, Faro A, Ren CL, Morgan W, Sanders DB. Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes. Jama Pediatrics. PMID 35913705 DOI: 10.1001/jamapediatrics.2022.2674 |
0.317 |
|
2022 |
Bouzek DC, Ren CL, Thompson M, Slaven JE, Sanders DB. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Pediatric Pulmonology. PMID 35429154 DOI: 10.1002/ppul.25925 |
0.354 |
|
2022 |
Perrem L, Stanojevic S, Solomon M, Grasemann H, Sweezey N, Waters V, Sanders DB, Davis SD, Ratjen F. Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls. Thorax. PMID 35428702 DOI: 10.1136/thoraxjnl-2021-218347 |
0.312 |
|
2022 |
Gold LS, Hansen RN, Patrick DL, Tabah A, Heltshe SL, Flume PA, Goss CH, West NE, Sanders DB, VanDevanter DR, Kessler L. Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 35300932 DOI: 10.1016/j.jcf.2022.03.001 |
0.36 |
|
2021 |
Madde A, Okoniewski W, Sanders DB, Ren CL, Weiner DJ, Forno E. Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 34972650 DOI: 10.1016/j.jcf.2021.12.014 |
0.325 |
|
2021 |
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA. A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine. PMID 34469706 DOI: 10.1164/rccm.202102-0461OC |
0.402 |
|
2021 |
Pittman JE, Khan U, Laguna TA, Heltshe S, Goss CH, Sanders DB. Rates of adverse and serious adverse events in children with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 33745860 DOI: 10.1016/j.jcf.2021.02.013 |
0.306 |
|
2021 |
Sanders DB, Slaven JE, Maguiness K, Chmiel JF, Ren CL. Early Life Height Attainment in Cystic Fibrosis Is Associated with Pulmonary Function at Age 6 Years. Annals of the American Thoracic Society. PMID 33476226 DOI: 10.1513/AnnalsATS.202008-933OC |
0.333 |
|
2021 |
Patel S, Thompson MD, Slaven JE, Sanders DB, Ren CL. Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic. Pediatric Pulmonology. PMID 33434352 DOI: 10.1002/ppul.25250 |
0.377 |
|
2020 |
Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, ... Sanders DB, et al. Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. PMID 33030967 DOI: 10.1164/rccm.202006-2433OC |
0.305 |
|
2020 |
Hoppe JE, Hinds DM, Colborg A, Wagner BD, Morgan WJ, Rosenfeld M, Zemanick ET, Sanders DB. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatric Pulmonology. PMID 32970375 DOI: 10.1002/ppul.25092 |
0.378 |
|
2019 |
Dasenbrook EC, Fink AK, Schechter MS, Sanders DB, Millar SJ, Pasta DJ, Mayer-Hamblett N. Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 31870629 DOI: 10.1016/j.jcf.2019.12.005 |
0.301 |
|
2019 |
Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ. Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 31257102 DOI: 10.1016/J.Jcf.2019.06.008 |
0.494 |
|
2019 |
Hinds DM, Sanders DB, Slaven JE, Romero M, Davis SD, Stevens JC. Cystic fibrosis in El Salvador. Pediatric Pulmonology. PMID 30694614 DOI: 10.1002/Ppul.24232 |
0.345 |
|
2019 |
Kopp BT, Thompson R, Kim J, Konstan R, Diaz A, Smith B, Shrestha C, Rogers LK, Hayes D, Tumin D, Woodley FW, Ramilo O, Sanders DB, Groner JA, Mejias A. Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis. Thorax. PMID 30661024 DOI: 10.1136/Thoraxjnl-2018-211845 |
0.366 |
|
2018 |
Sanders DB, Li Z, Parker-McGill K, Farrell P, Brody AS. Quantitative chest computerized tomography and FEV equally identify pulmonary exacerbation risk in children with cystic fibrosis. Pediatric Pulmonology. PMID 30160050 DOI: 10.1002/Ppul.24144 |
0.472 |
|
2018 |
Sanders DB, Zhang Z, Farrell PM, Lai HJ. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 29396025 DOI: 10.1016/J.Jcf.2018.01.006 |
0.42 |
|
2018 |
Flume P, Heltshe S, West N, Vandevanter D, Sanders D, Skalland M, Beckett V, Goss C. P094 Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations Journal of Cystic Fibrosis. 17: S85. DOI: 10.1016/s1569-1993(18)30390-4 |
0.346 |
|
2017 |
Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials. PMID 29170074 DOI: 10.1016/J.Cct.2017.11.012 |
0.446 |
|
2017 |
Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB, Gibson RL, Morgan W, Rosenfeld M. Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 29110966 DOI: 10.1016/J.Jcf.2017.10.008 |
0.385 |
|
2017 |
Sanders DB, Zhao Q, Li Z, Farrell PM. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes. Pediatric Pulmonology. PMID 28881091 DOI: 10.1002/Ppul.23765 |
0.433 |
|
2017 |
Sanders DB, Li Z, Zhao Q, Farrell PM. Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 28765072 DOI: 10.1016/J.Jcf.2017.07.003 |
0.464 |
|
2017 |
Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 28460885 DOI: 10.1016/J.Jcf.2017.04.005 |
0.488 |
|
2017 |
West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA. Standardized Treatment of Pulmonary exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 28457954 DOI: 10.1016/J.Jcf.2017.04.003 |
0.423 |
|
2017 |
VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Jain R, Sanders DB, Goss CH, Flume PA. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 28438499 DOI: 10.1016/J.Jcf.2017.04.004 |
0.426 |
|
2017 |
Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, et al. Diagnosis of Cystic Fibrosis in Screened Populations. The Journal of Pediatrics. 181: S33-S44.e2. PMID 28129810 DOI: 10.1016/J.Jpeds.2016.09.065 |
0.345 |
|
2016 |
Sanders DB, Fink AK. Background and Epidemiology. Pediatric Clinics of North America. 63: 567-84. PMID 27469176 DOI: 10.1016/J.Pcl.2016.04.001 |
0.409 |
|
2015 |
Boyer D, Nevin M, Thomson CC, Sanders DB, Alexiou S, Goldfarb SB, Nicholas JL, Thacker PG, Coverstone AM, Faro A, Cheng G, Majid A, Moore PE. ATS Core Curriculum 2015: Part III. Pediatric Pulmonary Medicine. Annals of the American Thoracic Society. 12: 1688-96. PMID 26540419 DOI: 10.1513/Annalsats.201506-322Cme |
0.386 |
|
2015 |
Sanders DB. The epidemiology of poor outcomes after pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 26476777 DOI: 10.1016/J.Jcf.2015.10.002 |
0.373 |
|
2015 |
Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. The Journal of Pediatrics. PMID 26340874 DOI: 10.1016/J.Jpeds.2015.07.044 |
0.441 |
|
2015 |
Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M. Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society. 12: 1170-6. PMID 26288390 DOI: 10.1513/Annalsats.201504-198Oc |
0.428 |
|
2015 |
Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatric Pulmonology. 50: 763-70. PMID 26061914 DOI: 10.1002/Ppul.23217 |
0.38 |
|
2015 |
Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics. 135: e1386-92. PMID 25963008 DOI: 10.1542/Peds.2014-3698 |
0.369 |
|
2015 |
Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. PMID 25911223 DOI: 10.1136/Thoraxjnl-2014-206750 |
0.427 |
|
2015 |
Sanders DB, Li Z, Brody AS. Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis. Annals of the American Thoracic Society. 12: 64-9. PMID 25474182 DOI: 10.1513/Annalsats.201407-338Oc |
0.397 |
|
2015 |
Goss C, Heltshe S, Thompson V, West N, Sanders D, VanDevanter D, Flume P. 189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response Journal of Cystic Fibrosis. 14: S106. DOI: 10.1016/S1569-1993(15)30366-0 |
0.364 |
|
2015 |
Sanders D, Goss C, VanDevanter D, Heltse S, Thompson V, Flume P. 188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations Journal of Cystic Fibrosis. 14: S106. DOI: 10.1016/S1569-1993(15)30365-9 |
0.416 |
|
2015 |
West N, Goss C, VanDevanter D, Heltshe S, Thompson V, Sanders D, Flume P. WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations Journal of Cystic Fibrosis. 14: S13. DOI: 10.1016/S1569-1993(15)30039-4 |
0.426 |
|
2014 |
Sanders DB. Phenotypes that matter: Pseudomonas aeruginosa and progression of cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine. 190: 245-6. PMID 25084257 DOI: 10.1164/Rccm.201406-1145Ed |
0.419 |
|
2014 |
Sanders DB, Li Z, Laxova A, Rock MJ, Levy H, Collins J, Ferec C, Farrell PM. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Annals of the American Thoracic Society. 11: 63-72. PMID 24261460 DOI: 10.1513/Annalsats.201309-303Oc |
0.46 |
|
2013 |
Sanders DB, Goss CH. Pulmonary exacerbations as indicators of progression of lung disease in young children with CF. Thorax. 68: 608-9. PMID 23542463 DOI: 10.1136/Thoraxjnl-2013-203262 |
0.485 |
|
2012 |
Sanders DB, Farrell PM. Transformative mutation specific pharmacotherapy for cystic fibrosis. Bmj (Clinical Research Ed.). 344: e79. PMID 22232540 DOI: 10.1136/Bmj.E79 |
0.441 |
|
2012 |
Sanders DB, Li Z, Rock MJ, Brody AS, Farrell PM. The sensitivity of lung disease surrogates in detecting chest CT abnormalities in children with cystic fibrosis. Pediatric Pulmonology. 47: 567-73. PMID 22170734 DOI: 10.1002/Ppul.21621 |
0.39 |
|
2012 |
Li Z, Sanders DB, Rock MJ, Kosorok MR, Collins J, Green CG, Brody AS, Farrell PM. Regional differences in the evolution of lung disease in children with cystic fibrosis. Pediatric Pulmonology. 47: 635-40. PMID 22162514 DOI: 10.1002/Ppul.21604 |
0.407 |
|
2012 |
Sanders DB, Lai HJ, Rock MJ, Farrell PM. Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 11: 150-3. PMID 22104951 DOI: 10.1016/J.Jcf.2011.10.002 |
0.36 |
|
2011 |
Sanders DB, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 184: 816-21. PMID 21737586 DOI: 10.1164/Rccm.201105-0816Oc |
0.414 |
|
2011 |
Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatric Pulmonology. 46: 393-400. PMID 20967845 DOI: 10.1002/Ppul.21374 |
0.477 |
|
2010 |
Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. American Journal of Respiratory and Critical Care Medicine. 182: 627-32. PMID 20463179 DOI: 10.1164/rccm.200909-1421OC |
0.382 |
|
2010 |
Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatric Pulmonology. 45: 127-34. PMID 20054859 DOI: 10.1002/Ppul.21117 |
0.488 |
|
2010 |
Sanders D, Li Z, Rock M, Brody A, Collins J, Farrell P. The sensitivity of lung disease surrogates in children with CF: limited value of FEV1 Journal of Cystic Fibrosis. 9: S110. DOI: 10.1016/S1569-1993(10)60426-2 |
0.304 |
|
2010 |
Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis (Pediatric Pulmonology (2010) 45, 2 (127-134) DOI: 10.1002/ppul.21117) Pediatric Pulmonology. 45: 521-522. DOI: 10.1002/Ppul.21249 |
0.356 |
|
2008 |
Sanders DB, Rosenfeld M, Mayer-Hamblett N, Stamey D, Redding GJ. Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. Pediatric Pulmonology. 43: 1142-6. PMID 18846562 DOI: 10.1002/Ppul.20924 |
0.325 |
|
Show low-probability matches. |